Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.62 USD | +6.12% | +5.87% | +63.80% |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+63.91% | 1.35B | C- | ||
-2.73% | 103B | B+ | ||
+1.30% | 95.28B | B+ | ||
+1.86% | 22.15B | B | ||
-15.53% | 21.02B | B+ | ||
-8.45% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-13.43% | 16.05B | B | ||
+3.84% | 13.68B | C+ | ||
+34.82% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SYRE Stock
- Ratings Spyre Therapeutics, Inc.